BioNTech SE - ADR
NASDAQ:BNTX 1:51:13 PM EDT
| Market Cap (Intraday) | 20.61B |
| Current PE | 22.16 |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $88.58 |
| 50-Day MA | $91.78 |
| 200-Day MA | $101.73 |
BioNTech SE - ADR Stock, NASDAQ:BNTX
An der Goldgrube 12, Mainz, Rheinland-Pfalz 55131
Germany
Phone: +49.6131.9084.0
Number of Employees: 3082
Description
BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.